Abstract
We report here a 34-year-old woman with complicated severe opportunistic pulmonary infection, who was treated with the newly developed antibiotics quinupristin/dalfopristin (QPR/DPR) and voriconazole. She had received repeated chemotherapy, irradiation of the left lung, autologous and allogeneic bone marrow transplantation (BMT), and segmentectomy of the base of the left lung as treatments for Hodgkin's lymphoma. Although she had been in complete remission (CR), the structure of the left lung was severely degraded. Four years after achieving CR, she developed complicated life-threatening pulmonary infections with methicillin-resistant Staphylococcus epidermidis and Aspergillus niger during outpatient care. Chemotherapies with QPR/DPR for S. epidermidis pneumonia and voriconazole for chronic necrotizing pulmonary aspergillosis (CNPA) improved her symptoms rapidly without any major complications. QPR/DPR and voriconazole are considered effective for patients with life-threatening opportunistic pulmonary infections who have previously been treated with intensive regimens including radiotherapies to the lung.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
GW King B Yanes PE Hurtubise SP Balcerzak AF LoBuglio (1976) ArticleTitleImmune function of successfully treated lymphoma patients J Clin Invest 57 1451–60 Occurrence Handle932190 Occurrence Handle1:STN:280:DyaE283htlKguw%3D%3D Occurrence Handle10.1172/JCI108415
JN Maslow ME Mulligan RD Arbeit (1993) ArticleTitleMolecular epidemiology: application of contemporary techniques to the typing of microorganisms Clin Infect Dis 17 153–64 Occurrence Handle8399860 Occurrence Handle1:STN:280:DyaK2c%2Fgt1Olug%3D%3D
InstitutionalAuthorNameAventis Pharma Japan (2002) Summary of the efficacy data of synercid against VREF: infections in the emergency use programs. Code No. DIR020032; in house information Aventis Pharma Japan Tokyo
J Larkin L Busciglio H Fontanet G Gamouras (1998) ArticleTitle Staphylococcus epidermidis endocarditis treated with RP 59500 (quinupristin/dalfopristin) Clin Infect Dis 26 1239–40 Occurrence Handle9597268 Occurrence Handle1:STN:280:DyaK1c3lvFGmtA%3D%3D Occurrence Handle10.1086/598358
E Mundlein H von Baum HK Geiss M Springsklee M Zeier K Andrassy (1997) ArticleTitleLife-threatening infection with multiresistant Staphylococcus epidermidis in a patient with end-stage renal disease: cure with chloramphenicol and quinupristin/dalfopristin (RP 59500) Infection 25 252–4 Occurrence Handle9266267 Occurrence Handle10.1007/BF01713157 Occurrence Handle1:STN:280:DyaK2svhtFaruw%3D%3D
MA John C Pletch Z Hussain (2002) ArticleTitleIn vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci J Antimicrob Chemother 50 933–8 Occurrence Handle12461014 Occurrence Handle10.1093/jac/dkf241 Occurrence Handle1:CAS:528:DC%2BD38XptlOitro%3D
SH Hwang MN Kim CH Pai DH Huh WS Shin (2000) ArticleTitleIn vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea Yonsei Med J 41 563–9 Occurrence Handle11079615 Occurrence Handle1:CAS:528:DC%2BD3cXotlyksb4%3D
DO Garrett E Jochimsen K Murfitt B Hill S McAllister P Nelson et al. (1999) ArticleTitleThe emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis Infect Control Hosp Epidemiol 20 167–70 Occurrence Handle10100541 Occurrence Handle10.1086/501605 Occurrence Handle1:STN:280:DyaK1M7pvVKnsg%3D%3D
RE Binder LJ Faling RD Pugatch C Mahasaen GL Snider (1982) ArticleTitleChronic necrotizing pulmonary aspergillosis: a discrete clinical entity Medicine 61 109–24 Occurrence Handle7038373 Occurrence Handle10.1097/00005792-198203000-00005 Occurrence Handle1:STN:280:DyaL387kslOiuw%3D%3D
F Ikeda (2003) ArticleTitleAntifungal activity and clinical efficacy of micafungin sodium (Funguard) (in Japanese) Nippon Yakurigaku Zasshi 122 339–44 Occurrence Handle14501170 Occurrence Handle1:CAS:528:DC%2BD3sXnvVait70%3D
T Terashima H Nakamura K Naoki Y Suzuki M Kanazawa T Kawashiro (1993) ArticleTitleA case of chronic necrotizing pulmonary aspergillosis treated with itraconazole (in Japanese) Nihon Kyobu Shikkan Gakkai Zasshi 31 1180–4 Occurrence Handle8255032 Occurrence Handle1:STN:280:DyaK2c%2Fns1Ontg%3D%3D
R Herbrecht DW Denning TF Patterson JE Bennett RE Greene JW Oestmann InstitutionalAuthorNameInvasive Fungal Infections Group of the European Organisation for Research InstitutionalAuthorNameTreatment of Cancer and the Global Aspergillus Study Group et al. (2002) ArticleTitleVoriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 408–15 Occurrence Handle12167683 Occurrence Handle10.1056/NEJMoa020191 Occurrence Handle1:CAS:528:DC%2BD38XlvFKrt7o%3D
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Muto, H., Kaneko, S., Machino, T. et al. Quinupristin/dalfopristin and voriconazole controlled Staphylococcus epidermidis pneumonia and chronic necrotizing aspergillosis in a patient with severe lung degradation consequent to multiple treatments for Hodgkin's lymphoma. J Infect Chemother 12, 391–395 (2006). https://doi.org/10.1007/s10156-006-0495-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10156-006-0495-2